BioCentury
ARTICLE | Clinical News

Valneva's antibacterial vaccine meets in Phase II

December 1, 2015 3:11 AM UTC

Valneva SE (Euronext:VLA; VSE:VLA) said its VLA84 vaccine met the primary endpoint in a Phase II study to prevent Clostridium difficile infection.

The study included 500 healthy volunteers who received a 75 ug intramuscular vaccine dose without an alum adjuvant, a 200 ug dose with or without the adjuvant, or placebo, administered at days 0, 7 and 28. Valneva said the vaccine induced immune responses to both C. difficile toxins A and B at all doses, and said the 200 ug dose without alum led to the highest seroconversion rate against both toxins A and B on day 56. ...